Hansoh Pharmaceutical Group Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Huijuan Zhong
Chief executive officer
CN¥11.9m
Total compensation
| CEO salary percentage | 26.83% |
| CEO tenure | 10.1yrs |
| CEO ownership | n/a |
| Management average tenure | 6.1yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Are Investors Undervaluing Hansoh Pharmaceutical Group Company Limited (HKG:3692) By 27%?
Jan 07
Hansoh Pharmaceutical Group Company Limited Just Beat Revenue Estimates By 13%
Aug 22Earnings Not Telling The Story For Hansoh Pharmaceutical Group Company Limited (HKG:3692) After Shares Rise 28%
Jul 29A Look At The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 06We Take A Look At Why Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Compensation Is Well Earned
Jun 13Subdued Growth No Barrier To Hansoh Pharmaceutical Group Company Limited (HKG:3692) With Shares Advancing 31%
Jun 11Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
May 21Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 31Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Mar 23Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Feb 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | CN¥5b |
| Mar 31 2025 | n/a | n/a | CN¥5b |
| Dec 31 2024 | CN¥12m | CN¥3m | CN¥4b |
| Sep 30 2024 | n/a | n/a | CN¥5b |
| Jun 30 2024 | n/a | n/a | CN¥5b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥15m | CN¥7m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥3b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥11m | CN¥5m | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥3b |
| Dec 31 2021 | CN¥16m | CN¥8m | CN¥3b |
Compensation vs Market: Huijuan's total compensation ($USD1.71M) is above average for companies of similar size in the Hong Kong market ($USD875.43K).
Compensation vs Earnings: Huijuan's compensation has been consistent with company performance over the past year.
CEO
Huijuan Zhong (63 yo)
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015 and served as its President since December 2, 2015....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.1yrs | CN¥11.93m | no data | |
| Executive Director | 9.8yrs | CN¥7.48m | 0.029% HK$ 72.9m | |
| Executive Director | 10.1yrs | CN¥19.04m | 0.037% HK$ 93.1m | |
| Chief Financial Officer | no data | no data | no data | |
| Chief Technology Officer | 1.4yrs | no data | no data | |
| Chief Science Officer | 3.8yrs | no data | no data | |
| Senior Vice President | 16.8yrs | no data | no data | |
| Chief Business Officer | 4.8yrs | no data | no data | |
| Chief Medical Officer | 1.8yrs | no data | no data | |
| Joint Company Secretary & Senior VP | 7.4yrs | no data | no data | |
| Joint Company Secretary | 1yr | no data | no data |
Experienced Management: 3692's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.1yrs | CN¥11.93m | no data | |
| Executive Director | 9.8yrs | CN¥7.48m | 0.029% HK$ 72.9m | |
| Executive Director | 10.1yrs | CN¥19.04m | 0.037% HK$ 93.1m | |
| Independent Non-Executive Director | 6.7yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: 3692's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/14 16:30 |
| End of Day Share Price | 2026/01/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansoh Pharmaceutical Group Company Limited is covered by 39 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |